The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects

Autor:	David E. Anderson, Thomas N. Kakuda, PJ Ruane, M Ramgopal, R Ryan, Bruce Coate, Cynthia Brinson, M Cho
Rok vydání:	2015
Předmět:	medicine.medical_specialty education.field_of_study business.industry Health Policy Population Etravirine Surgery Regimen Infectious Diseases Tolerability Internal medicine Pharmacodynamics Medicine Pharmacology (medical) Ritonavir business education Viral load Darunavir medicine.drug
Zdroj:	HIV Medicine. 16:288-296
ISSN:	1464-2662
Popis:	Objectives Following antiretroviral therapy failure, patients are often treated with a three-drug regimen that includes two nucleoside/tide reverse transcriptase inhibitors [N(t)RTIs]. An alternative two-drug nucleoside-sparing regimen may decrease the pill burden and drug toxicities associated with the use of N(t)RTIs. The Intelence aNd pRezista Once A Day Study (INROADS; NCT01199939) evaluated the nucleoside-sparing regimen of etravirine 400 mg with darunavir/ritonavir 800/100 mg once-daily in HIV-1-infected treatment-experienced subjects or treatment-naive subjects with transmitted resistance. Methods In this exploratory phase 2b, single-arm, open-label, multicentre, 48-week study, the primary endpoint was the proportion of subjects who achieved HIV-1 RNA
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::cf19ddce35c736bddcb9892f91c83185 https://doi.org/10.1111/hiv.12211 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.